Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.46 |
| ▸ | IL2 | P60568 | 2/20 | 0.45 |
| ▸ | ESRRG | P62508 | 5/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766380 | 0.97 | STIM1 (0.47) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL16362066 | 0.86 | STIM1 (0.58) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL17766401 | 0.85 | STIM1 (0.59) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL17766344 | 0.85 | STIM1 (0.48) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL17766387 | 0.84 | STIM1 (0.49) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL17766345 | 0.82 | CRACR2A (0.42) | STIM1ORAI1IL2ASAH1MAOA | |
| SCHEMBL17766400 | 0.78 | IL2 (0.53) | STIM1ORAI1IL2TP53SMN1; SMN2 | |
| SCHEMBL17766374 | 0.78 | STIM1 (0.50) | STIM1ORAI1IL2ESRRGS1PR2 | |
| SCHEMBL16321066 | 0.76 | KDM1A (0.39) | STIM1ORAI1IL2ASAH1MAPT | |
| SCHEMBL17766405 | 0.76 | IL2 (0.49) | STIM1ORAI1IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | STIM1 303/4885ORAI1 6/4885IL2 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.